Aoxing Pharmaceutical (AOXG) Inactive 10-Q2014 Q1 Quarterly report

Filed: 14 Nov 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: abuse, alfentanil, alter, Amex, anaesthesia, analgesic, attach, AXN, began, body, brain, broad, cent, Chairman, chemical, commitment, constitute, consumption, Convention, coordinate, cord, cough, created, crime, customer, decade, dextropropoxyphene, diarrhoea, dihydrocodeine, diphenoxylate, dramatically, EDL, essential, ethylmorphine, Euronext, extension, extent, fail, fentanyl, forward, gastrointestinal, harvest, healthy, heroin, hydrocodone, hydromorphone, illicit, inability, INCB, inclusion, induce, interfere, key, legal, lesser, liquidated, Liquidity, loosening, marked, Member, methadone, mild, NYSE, onemajor, onset, opioid, outcome, Pacific, paid, papaverine, patient, perception, pethidine, pill, plant, policy, prescribed, preserve, prevention, problem, proportionate, propoxyphene, psychotropic, reclassification, reduction, reimbursable, relicensed, relieve, remifentanil, repayment, restore, return, satisfy, scientific, season, sensation, Single, situation, sound, specific, spinal, split, strongest, structure, supplement, supply, surface, suspending, symbol, synthetic, thebaine, ticker, tract, trading, trafficking, transfer, transmission, treat, uncertainty, undertook, universal, Worldwide, XinleCity, Yue, Zhenjiang

Removed: affiliated, amortization, amortized, attention, bridge, certified, CITIC, Codification, compliance, comprised, convertible, decline, deliver, demonstrated, designing, dilution, efficacy, enable, ensuring, fee, fourth, governmental, high, identifiable, improvement, independent, injection, intellectual, involved, life, local, low, maintain, managed, managing, medicinal, month, negatively, partially, perform, performance, performed, positive, prescription, presently, quality, regulatory, reliable, retail, rural, safety, sell, senior, setting, Shuanghuanglian, tangible, test, tested, testing, therapeutic, timely, unit, Xinle

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

AOXG similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION

CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. §1350

In connection with the Quarterly Report on Form 10-Q of Aoxing Pharmaceutical Company, Inc. (the “Company”) for the fiscal period ended September 30, 2013 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Guoan Zhang, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for said period.

November 14, 2013	/s/ GuoanZhang
	GuoanZhang, Acting Chief Financial Officer

A signed original of this written statement has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.